

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

IN THE MATTER OF RULE-MAKING	:	AFFIRMATIVE ACTION
PROCEEDINGS BEFORE THE	:	ORDER OF THE
CONTROLLED SUBSTANCES BOARD	:	CONTROLLED SUBSTANCES BOARD

FINDINGS

1. On June 17, 2019, the Department of Justice, Drug Enforcement Administration published its final rules in the Federal Register placing Brexanolone and Solriamfetol into schedule IV of the federal Controlled Substances Act. The scheduling actions are effective June 17, 2019.
2. The Controlled Substances Board did not receive an objection to similarly treating Brexanolone and Solriamfetol as schedule IV under ch. 961, Stats. within 30 days of the date of publication in the federal register of the final order designating Brexanolone and Solriamfetol as controlled substances.
3. The Controlled Substances Board will promulgate a final rule, without making the determinations or findings required by ss. 961.11(1), (1m), (1r) and (2) or s. 961.19 and omitting the notice of proposed rule making, designating Brexanolone and Solriamfetol as schedule IV controlled substances.

ORDER

Pursuant to s. 961.11(4), Stats., the Controlled Substances Board by affirmative action similarly treats Brexanolone and Solriamfetol under chapter 961, Stats. by creating the following:

CSB 2.67 Addition of Brexanolone and Solriamfetol to schedule IV. Section 961.20 (2) (p) and (2m) (g), Stats., are created to read:

961.20 (2) (ap) Brexanolone.
(2m) (g) Solriamfetol.

This order shall take effect on July 22, 2019 to allow for publication in the Administrative Register. The order expires upon promulgation of a final rule.

Dated July 17, 2019



Doug Englebort, Chair
Controlled Substances Board